Get the Stockscreener App
237.14
0.94%
-2.26
After Hours:
237.14
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $237.14, with a volume of 775.62K.
It is down -0.94% in the last 24 hours and up +1.46% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$239.40
Open:
$235.38
24h Volume:
775.62K
Relative Volume:
0.83
Market Cap:
$26.17B
Revenue:
$11.28B
Net Income/Loss:
$1.07B
P/E Ratio:
26.16
EPS:
9.0657
Net Cash Flow:
$1.33B
1W Performance:
-2.32%
1M Performance:
+1.46%
6M Performance:
+13.76%
1Y Performance:
+31.66%
1-Day Range:
$235.38
$238.91
1-Week Range:
$235.38
$243.72
52-Week Range:
$171.18
$247.19
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, NTRA, IQV, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
237.14 | 26.63B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
613.78 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
207.66 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
328.18 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
267.77 | 42.15B | 16.63B | 1.39B | 2.12B | 8.0674 |
A
Agilent Technologies Inc
|
150.86 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Quest Diagnostics stock edges lower near 52-week highs after solid Q2 growth - AD HOC NEWS
Quest Diagnostics stock holds steady as investors await next earnings update - AD HOC NEWS
Man Group takes new $495K stake in Quest Diagnostics as stock nears record high - Dealroom
CEO of Quest Diagnostics (NYSE: DGX) sells 10,000 shares - Stock Titan
Quest Diagnostics Insider Sold Shares Worth $2,427,200, According to a Recent SEC Filing - marketscreener.com
Quest Diagnostics stock gains as investors focus on growth and fair value - AD HOC NEWS
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics stock trades near 52-week high as kidney testing deal lifts valuation - AD HOC NEWS
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Quest Diagnostics (NYSE: DGX) insider plans new sale after June $1.9M trade - Stock Titan
Quest Diagnostics SVP & general counsel sells $5.5m in shares - Investing.com Nigeria
Quest Diagnostics SVP & general counsel sells $5.5m in shares By Investing.com - Investing.com South Africa
Quest Diagnostics Inc. stock underperforms Monday when compared to competitors - MarketWatch
Quest Diagnostics (DGX) Stock Analysis: Navigating Growth Amidst a Competitive Landscape - DirectorsTalk Interviews
Quest Diagnostics stock holds steady as investors await fresh earnings catalysts - AD HOC NEWS
Quest Diagnostics (NYSE: DGX) holder to sell 22,677 shares - Stock Titan
Humanity Health Inc. And Quest Diagnostics Announce Availability Of Humanity Biological Age Analysis Through questhealth.com - marketscreener.com
Quest Diagnostics brings a $29 biological-age report to the U.S.—no extra blood draw - Stock Titan
Roche's Alzheimer's blood test gets FDA clearance; Quest plans U.S. launch - Stock Titan
Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology - Yahoo Finance
Quest Diagnostics stock holds near highs after Q2 beat - Ad-hoc-news.de
Is it the Right Time to Retain DGX Stock in Your Portfolio? - TradingView
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Trillium Asset Management LLC Takes $5.43 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
SGL Investment Advisors Inc. Buys Shares of 27,290 Quest Diagnostics Incorporated $DGX - MarketBeat
Danske Bank A S Buys Shares of 68,561 Quest Diagnostics Incorporated $DGX - MarketBeat
5,500 Shares in Quest Diagnostics Incorporated $DGX Acquired by Glaxis Capital Management LLC - MarketBeat
Edmond DE Rothschild Holding S.A. Invests $944,000 in Quest Diagnostics Incorporated $DGX - MarketBeat
Ceredex Value Advisors LLC Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
327,575 Shares in Quest Diagnostics Incorporated $DGX Bought by Advisors Capital Management LLC - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Quest Diagnostics stock extends 2026 rally after Q2 revenue and earnings beat - Ad-hoc-news.de
Tocqueville Asset Management L.P. Takes $22.67 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Wealthfront Advisers LLC Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Deutsche Bank AG Makes New $124.18 Million Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
BlackRock Inc. Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Analysts Offer Insights on Healthcare Companies: Quest Diagnostics (DGX) and Irhythm Technologies (IRTC) - The Globe and Mail
Quest Diagnostics stock hits a fresh high as Q2 earnings beat expectations - Ad-hoc-news.de
Quest Diagnostics stock hits all-time high at 240.15 USD - Investing.com
Quest Diagnostics stock hits all-time high at 240.15 USD By Investing.com - Investing.com Canada
M.D. Sass LLC Buys New Shares in Quest Diagnostics Incorporated $DGX - MarketBeat
Commerzbank Aktiengesellschaft FI Takes $1.42 Million Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Foster & Motley Inc. Makes New $3.51 Million Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Danica Pension Livsforsikringsaktieselskab Invests $2.26 Million in Quest Diagnostics Incorporated $DGX - MarketBeat
Alpine Woods Capital Investors LLC Acquires New Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics (DGX) Upgraded to Buy: Here's Why - Yahoo Finance
WHOOP opens blood tests to nonmembers and adds a test for signals tied to 50+ cancer types - Stock Titan
Nuance Investments LLC Takes Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Occidental Asset Management LLC Invests $6.12 Million in Quest Diagnostics Incorporated $DGX - MarketBeat
Cornerstone Advisors LLC Invests $10.01 Million in Quest Diagnostics Incorporated $DGX - MarketBeat
GSA Capital Partners LLP Purchases Shares of 4,971 Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):